[go: up one dir, main page]

NZ601871A - Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r - Google Patents

Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r

Info

Publication number
NZ601871A
NZ601871A NZ601871A NZ60187106A NZ601871A NZ 601871 A NZ601871 A NZ 601871A NZ 601871 A NZ601871 A NZ 601871A NZ 60187106 A NZ60187106 A NZ 60187106A NZ 601871 A NZ601871 A NZ 601871A
Authority
NZ
New Zealand
Prior art keywords
antibody
bind
diseases
compositions
treatment
Prior art date
Application number
NZ601871A
Inventor
Anan Chuntharapai
Terence Wong
Wenjun Ouyang
Yan Zheng
Yvonne Chen
Susan Sa
Jianfeng Wu
Patricia Valdez
Dimitry Danilenko
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to NZ621483A priority Critical patent/NZ621483A/en
Publication of NZ601871A publication Critical patent/NZ601871A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed is an antibody that specifically binds to IL-22, wherein the antibody is: (a) an antibody produced by a hybridoma selected from 3F11.3 (ATCC Accession No. PTA-7312), and hybridoma 8E11.9 (ATCC Accession No. PTA-7319); (b) an affinity matured form of the antibody of (a); (c) an antigen-binding fragment of the antibody of (a) or (b); or (d) a humanised form of the antibody of (a), (b), or (c). Also disclosed is the use of said antibody in the preparation of a pharmaceutical composition for alleviating a disorder characterised by skin inflammation.
NZ601871A 2005-12-02 2006-11-30 Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r NZ601871A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ621483A NZ621483A (en) 2005-12-02 2006-11-30 Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74164005P 2005-12-02 2005-12-02
US82259706P 2006-08-16 2006-08-16
NZ56877706 2006-11-30

Publications (1)

Publication Number Publication Date
NZ601871A true NZ601871A (en) 2014-10-31

Family

ID=51796516

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ601871A NZ601871A (en) 2005-12-02 2006-11-30 Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r

Country Status (1)

Country Link
NZ (1) NZ601871A (en)

Similar Documents

Publication Publication Date Title
NZ621483A (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
SG153878A1 (en) Chimeric and humanised monoclonal antibodies against inteleukin-13
RU2474588C2 (en) Cross-reactive antibodies anti-il-17a/il-17f and methods for use thereof
NZ602166A (en) Antibodies to il-6 and use thereof
WO2021055253A3 (en) Anti-tnfr2 antibodies and methods of use
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
JP2018534933A5 (en)
WO2005110474A3 (en) HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
HRP20100521T1 (en) MONOCLONAL ANTIBODIES AGAINST HEPATocyte GROWTH FACTORS
FI3487882T3 (en) GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BINDE GPRC5D AND CD3, AND THEIR USES
UA94060C2 (en) Monoclonal antibodies that specifically binds alk-1
UA90457C2 (en) Human monoclonal antibody that specifically binds to human m-csf
WO2005115452A3 (en) Fcϝriib-specific antibodies and methods of use thereof
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
NZ595235A (en) Compositions and methods for increasing muscle growth
UA98332C2 (en) Monoclonal antibody against cd44 that mediates cytotoxicity in cancer cells
NZ616992A (en) Anti-ilt7 antibody
WO2009140348A4 (en) Anti-il-6/il-6r antibodies and methods of use thereof
MY153893A (en) Antibodies against human il17 and uses thereof
MY149630A (en) Antibodies against amyloid-beta peptide
HRP20221471T1 (en) Anti-fgfr3 antibodies and methods using same
CN102027015A (en) Anti-CXCR4 antibodies
NZ595011A (en) Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases
SI2768859T1 (en) IL17C ANTAGONISTS FOR TREATMENT OF INFLAMATORY DISORDERS
WO2004108766A3 (en) Anti-hgf-r antibodies and their use

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE MISSING INVENTOR HAS BEEN ADDED (1209144, SA, SUSAN; 1209147, WU, JIANFENG; 1328986, DANILENKO, DIMITRY, M.; 1328991, VALDEZ, PATRICIA, A.; 1328992, ZHENG, YAN; 1339084, CHEN, YVONNE; 3098195, CHUNTHARAPAI, ANAN, 826 ELLIS DRIVE, COLMA, CALIFORNIA 94015, US; 3098199, WONG, TERENCE, 312 SHELL GATE ROAD, ALAMEDA, CALIFORNIA 94501, US; 3107002, OUYANG, WENJUN, 1057 GALLEY LANE, FOSTER CITY, CALIFORNIA 94404, US)

Effective date: 20140127

ERR Error or correction

Free format text: THE INVENTOR HAS BEEN CORRECTED TO 1209142, DANILENKO, DIMITRY; 1209144, SA, SUSAN; 1209145, VALDEZ, PATRICIA; 1209147, WU, JIANFENG; 1328992, ZHENG, YAN; 1339084, CHEN, YVONNE; 3098195, CHUNTHARAPAI, ANAN, 826 ELLIS DRIVE, COLMA, CALIFORNIA 94015, US; 3098199, WONG, TERENCE, 312 SHELL GATE ROAD, ALAMEDA, CALIFORNIA 94501, US; 3107002, OUYANG, WENJUN, 1057 GALLEY LANE, FOSTER CITY, CALIFORNIA 94404, US

Effective date: 20141010

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 30 NOV 2016 BY AJ PARK

Effective date: 20150311

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 NOV 2017 BY THOMSON REUTERS

Effective date: 20161022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 NOV 2018 BY THOMSON REUTERS

Effective date: 20171012

LAPS Patent lapsed